Updates on Ramantamig, a Myeloma Trispecific Antibody | Mark Wildgust, PhD

Why Some Newly Diagnosed Myeloma Patients Don’t Reach a Deep Response |Jonathan Kaufman, MD

Multidisciplinary approaches to improve prognosis prediction | Claudio Cerchione, MD, PhD

Amyloidosis and immune profling in AL and ATTR amyloidosis | Philip McCarthy, MD

Taste Changes from Talquetamab -Talisman Study Insights | Rakesh Popat, PhD

Duffy Null- Could a Simple Blood Test Guide Your Myeloma Treatment? | Lauren Merz, MD

Advances in supportive care for multiple myeloma | Artur Jurczyszyn, MD

Can Epcoritamab Improve Outcomes in R-mini-CHOP Patients? | Chan Cheah, MD, PhD

How Race & Social Deprivation Shape Myeloma Outcomes | Hamza Hashmi, MD & Paul Gater

Stem Cell Boost vs Supportive Care for Prolonged Cytopenias After CAR-T | Cindy Varga, MD

Cilta-Cel Outside Specs: How Safe & Effective Is It in Relapsed Myeloma? | Azra Borogovac, MD

Treating Plasma Cell Leukemia: New Insights on Bispecific Antibodies | Mahmoud Gaballa, MD

Myeloma Maintenance: Daratumumab as an Alternative to Lenalidomide | Sridevi Rajeeve, MD

Bispecific Therapies in Myeloma: Preferences & Priorities | Thomas LeBlanc, MD

AI Assistant for Faster, Cleaner Data | JP Capdevila

Fitness analysis of Isa-VRD transplant ineligible myeloma patients | Enrique Ocio, MD

Circulating tumor cells (CTCs) improve myeloma risk stratification | Mattia D'Agostino, MD

REVIVE Trial : Dara + Bispecific in High-Risk Smoldering Myeloma | Ola Landgren, MD, PhD

New Talquetamab Combos Show Promise for Longer-Lasting Myeloma Control | Jeffrey Matous, MD

Choosing the Best Induction Therapy for Fit Patients With Myeloma | Jonathan Kaufman, MD

Can Patient Questionnaires Reduce the Need for Eye Exams with Belantamab?| Rakesh Popat, PhD

Teclistamab & CMV: Risks and Clinical Outcomes Explained | Samer Al Hadidi, MD

Can Sonrotoclax Improve Outcomes in t(11;14) Relapsed Myeloma? | Rakesh Popat, PhD

Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD